Agenus Inc. (AGEN)
NASDAQ: AGEN
· Real-Time Price · USD
4.78
-0.36 (-7.00%)
At close: Jun 17, 2025, 3:59 PM
4.92
3.04%
After-hours: Jun 17, 2025, 05:10 PM EDT
-7.00% (1D)
| Bid | 4.68 |
| Market Cap | 130.92M |
| Revenue (ttm) | 99.52M |
| Net Income (ttm) | -190.65M |
| EPS (ttm) | 29.61 |
| PE Ratio (ttm) | 0.16 |
| Forward PE | 4.69 |
| Analyst | Hold |
| Ask | 4.93 |
| Volume | 601,614 |
| Avg. Volume (20D) | 996,453 |
| Open | 5.10 |
| Previous Close | 5.14 |
| Day's Range | 4.75 - 5.17 |
| 52-Week Range | 1.38 - 18.74 |
| Beta | 1.43 |
About AGEN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AGEN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AGEN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+12.6%
Agenus shares are trading higher after HC Wainwrig...
Unlock content with
Pro Subscription
2 weeks ago
+21.07%
Agenus shares are trading higher after the company announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and Balstilimab.
